Literature DB >> 26596791

Aortic valve prosthesis-patient mismatch and exercise capacity in adult patients with congenital heart disease.

Ymkje J van Slooten1, Joost P van Melle2, Hendrik G Freling3, Berto J Bouma4, Arie Pj van Dijk5, Monique Rm Jongbloed6, Martijn C Post7, Gertjan T Sieswerda8, Anna Huis In 't Veld2, Tjark Ebels9, Adriaan A Voors2, Petronella G Pieper2.   

Abstract

OBJECTIVES: To report the prevalence of aortic valve prosthesis-patient mismatch (PPM) in an adult population with congenital heart disease (CHD) and its impact on exercise capacity. Adults with congenital heart disease (ACHD) with a history of aortic valve replacement may outgrow their prosthesis later in life. However, the prevalence and clinical consequences of aortic PPM in ACHD are presently unknown.
METHODS: From the national Dutch Congenital Corvitia (CONCOR) registry, we identified 207 ACHD with an aortic valve prosthesis for this cross-sectional cohort study. Severe PPM was defined as an indexed effective orifice area ≤0.65 cm2/m2 and moderate PPM as an indexed orifice area ≤0.85 cm2/m2 measured using echocardiography. Exercise capacity was reported as percentage of predicted exercise capacity (PPEC).
RESULTS: Of the 207 patients, 68% was male, 71% had a mechanical prosthesis and mean age at inclusion was 43.9 years ±11.4. The prevalence of PPM was 42%, comprising 23% severe PPM and 19% moderate PPM. Prevalence of PPM was higher in patients with mechanical prostheses (p<0.001). PPM was associated with poorer exercise capacity (mean PPEC 84% vs. 92%; p=0.048, mean difference =-8.3%, p=0.047). Mean follow-up was 2.6±1.1 years during which New York Heart Association (NYHA) class remained stable in most patients. PPM showed no significant effect on death or hospitalisation during follow-up (p=0.218).
CONCLUSIONS: In this study we report a high prevalence (42%) of PPM in ACHD with an aortic valve prosthesis and an independent association of PPM with diminished exercise capacity. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Mesh:

Year:  2015        PMID: 26596791     DOI: 10.1136/heartjnl-2015-308013

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  6 in total

Review 1.  Aortic valve repair in adult congenital heart disease.

Authors:  Evaldas Girdauskas; Johannes Petersen; Jörg Sachweh; Rainer Kozlik-Feldmann; Christoph Sinning; Carsten Rickers; Yskert von Kodolitsch; Hermann Reichenspurner
Journal:  Cardiovasc Diagn Ther       Date:  2018-12

2.  Longitudinal Changes in Exercise Capacity in Patients Who Underwent Ross Procedure and Mechanical Aortic Valve Replacement: Does the Type of Surgery Matter?

Authors:  Daiji Takajo; Vasudha Kota; Preetha P L Balakrishnan; Marjorie Gayanilo; Chenni Sriram; Sanjeev Aggarwal
Journal:  Pediatr Cardiol       Date:  2021-03-08       Impact factor: 1.655

Review 3.  Prosthesis-Patient Mismatch After Aortic Valve Replacement.

Authors:  Abdellaziz Dahou; Haïfa Mahjoub; Philippe Pibarot
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-11

4.  Patient-Prosthesis Mismatch in Contemporary Small-Size Mechanical Prostheses Does Not Impact Survival at 10 Years.

Authors:  Horea Feier; Mihaela Mocan; Andrei Grigorescu; Lucian Falnita; Marian Gaspar; Constantin-Tudor Luca
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-31

5.  Aortic valve replacement in sheep with a novel trileaflet mechanical heart valve prosthesis without anticoagulation.

Authors:  Tim Schaller; Michael Scharfschwerdt; Kathrin Schubert; Cornelia Prinz; Ulrich Lembke; Hans-Hinrich Sievers
Journal:  JTCVS Open       Date:  2021-05-29

6.  NT-proBNP and exercise capacity in adult patients with congenital heart disease and a prosthetic valve: a multicentre PROSTAVA study.

Authors:  R C Schoonbeek; P G Pieper; Y J van Slooten; H G Freling; G T Sieswerda; A P J van Dijk; M R M Jongbloed; M C Post; B J Bouma; R M F Berger; T Ebels; J P van Melle
Journal:  Neth Heart J       Date:  2016-11       Impact factor: 2.380

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.